APA (7th ed.) Citation

RE, W., BR, D., WH, S., RC, B., B, A., S, S., . . . RJ, A. (2016). Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial. Lancet (London, England), 387(10019), 661. https://doi.org/10.1016/S0140-6736(15)01041-7

Chicago Style (17th ed.) Citation

RE, Ware, et al. "Hydroxycarbamide Versus Chronic Transfusion for Maintenance of Transcranial Doppler Flow Velocities in Children with Sickle Cell Anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Multicentre, Open-label, Phase 3, Non-inferiority Trial." Lancet (London, England) 387, no. 10019 (2016): 661. https://doi.org/10.1016/S0140-6736(15)01041-7.

MLA (9th ed.) Citation

RE, Ware, et al. "Hydroxycarbamide Versus Chronic Transfusion for Maintenance of Transcranial Doppler Flow Velocities in Children with Sickle Cell Anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Multicentre, Open-label, Phase 3, Non-inferiority Trial." Lancet (London, England), vol. 387, no. 10019, 2016, p. 661, https://doi.org/10.1016/S0140-6736(15)01041-7.